EBS News and Press, Emergent Biosolutions Inc. From 04/03/20

The Food and Drug Administration is encouraging people who have recovered from COVID-19 , the disease caused by the novel coronavirus, to donate their blood plasma, which can be processed into an antibody product that can treat current patients. Based on the medical community's experience with...

Aimed at facilitating nationwide access to antibody-rich blood products for COVID-19 patients, the FDA has instituted an emergency investigational new drug application (eIND) process for convalescent plasma, with its SARS-CoV-2 antibodies, collected from people who have recovered from the ...

Emergent BioSolutions (NYSE: EBS ) inks a formal agreement with the U.S. government aimed at speeding up the development of a plasma-based therapy, COVID-HIG, a human hyperimmune (contains a lot of antibodies against SARS-CoV-2) product for the potential treatment of severely ill COVID-19 ...

BARDA to provide $14.5 million in funding to support development of COVID-Human Immune Globulin (COVID-HIG), a human plasma-derived therapy candidate being developed as a potential treatment for COVID-19 in severe hospitalized and high-risk patients NIAID to include COVID-HIG product can...

For stock investors, there really hasn't been anywhere to hide from the market debacle that's followed from the COVID-19 pandemic. All industries have been hit as investors dump risky assets. It isn't too surprising that shares of biotechnology companies have fallen along with the rest, since t...

CDMO agreement for NanoFlu to support pathway to licensure Expanded collaboration now includes NanoFlu and COVID-19 vaccine candidate GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement with Novavax, Inc. (NASDAQ:NVA...

On Tuesday, the Food and Drug Administration said it's facilitating access to the blood plasma of patients who have recovered from COVID-19 . Because those patients have fought off disease, their plasma should contain antibodies to SARS-CoV-2, which causes it. The agency outlined eligibility r...

The public crisis that is the COVID-19 pandemic has some companies scrambling to survive, and others working hard to contribute to solving the problem. Investors, meanwhile, are dumping stocks of the companies in the former category while optimistically buying up shares of companies that might s...

Healthcare organizations are working on a number of different types of treatments for COVID-19, repurposing old drugs, as well as developing new ones. However, the Food and Drug Administration (FDA) confirmed that it's working on developing a new type of treatment using the blood of patients who...

Last week, I wrote "it's time to take a step back, breathe deep, and objectively identify money-making opportunities," and I reminded investors that "if you were in cash during the top 10 best days in the stock market over the past 20 years, then your overall return is half what it would've ...